Confirmation of the cardiac safety of nolasiban in a randomised cohort of healthy female volunteers

Nolasiban is an orally active oxytocin receptor antagonist being developed to increase the efficiency of assisted reproductive technologies. This study evaluated the pharmacokinetics, pharmacodynamics, and cardiac safety of nolasiban in 45 healthy women of child-bearing age. Nolasiban was administer...

Descripción completa

Detalles Bibliográficos
Autores principales: Täubel, Jörg, Lorch, Ulrike, Spencer, Christopher S., Freier, Anne, Camilleri, Dorothée, Djumanov, Dilshat, Ferber, Georg, Marchand, Line, Gotteland, Jean-Pierre, Pohl, Oliver
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7973531/
https://www.ncbi.nlm.nih.gov/pubmed/33739022
http://dx.doi.org/10.1038/s41598-021-85650-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7973531/
https://www.ncbi.nlm.nih.gov/pubmed/33739022
http://dx.doi.org/10.1038/s41598-021-85650-3

Ejemplares similares